DCision Consult Solutions
DCision Consult can provide decision-ready competitive landscapes that allow you to have that information when you need it. We can look at a landscape from many different perspectives: product; indication; target; company etc. and provide the level of detail needed to support your needs.
We can provide one-off landscapes but also have experience of ongoing monitoring of landscapes for clients.
We have a current subscription to the pharma intelligence database BioMedTracker (Informa). We generally provide deliverables as powerpoint and excel but can also use Tableau for analysis and presentation as well as having a subscription to the full Adobe suite for further data visualisation.
DCision Consult has experience of providing regular updates in clear, concise format. Using a personal rather than automated approach has its advantages: capturing stories and information that at first-glance (and any glance for an automated system) appear to be out-of-scope but which contain that hidden gem of knowledge that can help you get ahead.
We can also add comment and perspective on stories and news and link to internal and external information in a meaningful way.
- Do you need to find prevalence data for an Orphan Drug Designation?
- Do you need to find a quality review article that describes the current landscape for a particular indication?
We are experienced in conducting methodical and reproducible literature searches. And developing search strategies that can assist with regulatory submissions or building competitive landscapes, for examples.
These are just some amongst the many research questions we have successfully answered for our clients:
How could we more accurately identify potential patients suffering a rare disease?
Which regions in a country were more likely to have patients with a specific indication, so we can direct valuable sales and marketing resources more effectively?
What are the potential indications that could benefit from a specific drug delivery device?
What are the reimbursement processes in different countries? How have other similar indications managed to achieve reimbursement?
What the regulatory, pricing & reimbursement events impacting USA, EU5, and China on a weekly basis?
What are the numbers of patients receiving a particular therapy?
What is the current standard of care for a particular indication?
Who are the current competitors for a drug in development? What will the picture look in 5-10 years? What would the likely disrupters or game-changers be in the space?
List of registered products in the EU for specific indications (due diligence for regulatory submissions)?